Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKL-006RTU injection in moderate/severe ARDS (Phase I/II)
ChiCTR2600129214Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GKL-006RTU in acute respiratory distress syndrome (ARDS), sponsored by Peking Union Medical College Hospital. Primary endpoint: Safety and tolerability evaluation indicators. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
GKL-006RTU
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2600129214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129214.